Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.


Biotechnology

Pharmaceutical

Therapeutics

Carbon Biosciences

Joel Schneider

Gillian Payne

Steve Dipalma

Sebastian Aguirre Kozlouski, Ph.D.

Yoshi Hashimoto

Jianming Qiu

Jeff Moffit, PhD, DABT

Beckett Hart

Robert M. Kotin

Amy Lurier

Sebastian Aguirre

Jeff Moffit

The Scientific and Research Team at Carbon Biosciences is responsible for advancing the company's gene therapy platform by conducting cutting-edge research on novel parvoviruses, optimizing gene delivery methods, and developing experimental models to target specific tissues. This team collaborates closely with translational biology and analytical development experts to innovate and refine therapeutic approaches, aiming to tackle some of the most challenging diseases with enhanced efficacy and safety profiles.

Scientific and Research Team

Leadership Team

Development Team

Scientific and Research Team

About

Team members

Other teams at Carbon Biosciences

Leadership Team

Development Team